Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome
Authors:
- 1 June 2019
- journal article
- research article
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 104 (6) , 1223-1232
Abstract
No abstract availableKeywords
Funding Information
- E-Rare
- Deutsche Forschungsgemeinschaft (SFB 974, ZE 524-10/1)
- Bundesministerium für Forschung, Technologie und Raumfahrt (01GM1519A, 01GM1519D, 01GM1902C)
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro (IG21614)
This publication has 56 references indexed in Scilit:
- LZTR1 is a regulator of RAS ubiquitination and signalingScience, 2018
- Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signalingHuman Molecular Genetics, 2018
- Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological interventionBiophysical Reviews, 2018
- An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequencesAmerican Journal of Medical Genetics Part A, 2015
- Noonan syndrome and clinically related disordersBest Practice & Research Clinical Endocrinology & Metabolism, 2011
- Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disordersHuman Mutation, 2010
- A restricted spectrum of NRAS mutations causes Noonan syndromeNature Genetics, 2009
- Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype phenotype relationships and overlap with Costello syndromeJournal of Medical Genetics, 2007
- Germline KRAS mutations cause Noonan syndromeNature Genetics, 2006
- The Guanine Nucleotide-Binding Switch in Three DimensionsScience, 2001